UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000010703
Receipt No. R000012509
Scientific Title The effects of vildagliptin in addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus
Date of disclosure of the study information 2013/05/13
Last modified on 2019/10/16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The effects of vildagliptin in addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus
Acronym The effects of vildagliptin in addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus
Scientific Title The effects of vildagliptin in addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus
Scientific Title:Acronym The effects of vildagliptin in addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus
Region
Japan

Condition
Condition type 2 diabetes mellitus undergoing hemodialysis
Classification by specialty
Endocrinology and Metabolism Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The purpose of this study is to evaluate the effect of vildagliptin addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Total daily dose of insulin and HbA1c(NGSP) at 0, 12 and 24 weeks after administration of vildagliptin
Mean amplitude of glycemic excursions
Safety and adherence
Key secondary outcomes Events of hypoglycemia
Body weight

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1)The patient who have poor glycemic control undergoing insulin therapy or judged that it was expectable to reduce the insulin dose in addition to vildagliptin
2)CPI<0.8
Key exclusion criteria 1) Severe ketosis, or diabetic coma or precoma, type1 diabetes
2) Severe liver dysfunction
3) Diarrhea or vomiting
4) Severe infection, before and after surgery, or severe trauma
5) History of lactic acidosis or pancreatitis
6) Severe cardiac or pulmonary dysfunction, such as shock, heart failure, myocardial infarction, and pulmonary embolism.
7) Dehydration
8) History of severe alcoholic abuse
9) Malnutrition, starvation, debility, pituitary dysfunction, and adrenal insufficiency
10) Pregnant female, female with possibility of pregnancy
11) Malignancy
12) History of hypersensitivity to targeted medication
13) Patients inappropriate for medical reason
Target sample size 40

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kazuaki Soejima
Organization Saiseikai Kumamoto Hospital
Division name Kidney and Urology center
Zip code
Address 5-3-1 Chikami Minami-ku Kumamoto
TEL 096-351-8000
Email kazuaki-soejima@saiseikaikumamoto.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hironobu Inoue
Organization Saiseikai Kumamoto Hospital
Division name Kidney and Urology center
Zip code
Address 5-3-1 Chikami Minami-ku Kumamoto
TEL 096-351-8000
Homepage URL
Email hironobu-inoue@saiseiakikumamoto.jp

Sponsor
Institute Saiseikai Kumamoto Hospital
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 済生会熊本病院

Other administrative information
Date of disclosure of the study information
2013 Year 05 Month 13 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2013 Year 05 Month 01 Day
Date of IRB
2013 Year 05 Month 13 Day
Anticipated trial start date
2013 Year 05 Month 13 Day
Last follow-up date
2014 Year 05 Month 13 Day
Date of closure to data entry
2014 Year 05 Month 13 Day
Date trial data considered complete
2014 Year 05 Month 13 Day
Date analysis concluded
2014 Year 12 Month 31 Day

Other
Other related information The purpose of this study is to evaluate the effect of vildagliptin addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus.

Management information
Registered date
2013 Year 05 Month 13 Day
Last modified on
2019 Year 10 Month 16 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012509

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.